8-K: RxSight Reports Strong Second Quarter Growth Driven by Light Adjustable Lens Sales

RxSight, Inc. announced a 68% increase in revenue for the second quarter of 2024, driven by strong sales of its Light Adjustable Lens and Light Delivery Devices.

Summary

• RxSight reported a significant 68% increase in revenue for the second quarter of 2024, reaching $34.9 million, compared to $20.8 million in the same period last year.
• This growth was primarily fueled by a 92% increase in Light Adjustable Lens (LAL) revenue and a 32% increase in Light Delivery Device (LDD) revenue.
• The company sold 24,214 LALs, a 92% increase in procedure volume, and 78 LDDs, a 16% increase in unit sales, expanding the installed base to 810 LDDs.
• Gross profit for the quarter was $24.3 million, or 69.5% of revenue, a 102% increase compared to the second quarter of 2023.
• Operating expenses increased by 27% to $32.6 million, reflecting investments in growing the LDD installed base and supporting increased LAL sales.
• The company reported a net loss of $(6.1) million, or $(0.16) per share, compared to a net loss of $(13.8) million, or $(0.40) per share in the second quarter of 2023.
• Adjusted net earnings were $0.0 million, or $0.00 per share, compared to an adjusted net loss of $(9.5) million, or $(0.28) per share in the second quarter of 2023.
• Cash, cash equivalents, and short-term investments totaled $233.3 million as of June 30, 2024, including $107.5 million from a recent public offering.
• RxSight increased its full-year 2024 revenue guidance to $139.0 million to $140.0 million and operating expense guidance to $135.0 million to $136.0 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, improved profitability, and increased guidance. The company's technology is gaining traction, and the recent capital raise strengthens its financial position. However, the company is still operating at a loss, which prevents a perfect score.

Positives

• The company experienced significant revenue growth of 68% year-over-year.
• There was a substantial increase in LAL sales, with a 92% rise in procedure volume.
• The installed base of LDDs grew by 55% compared to the same quarter last year.
• Gross profit margin improved to 69.5%, up from 57.8% in the second quarter of 2023.
• The net loss per share improved from $(0.40) to $(0.16) year-over-year.
• The company's cash position is strong at $233.3 million, boosted by a recent capital raise.
• The company increased its full-year revenue guidance, indicating confidence in future performance.

Negatives

• The company still reported a net loss of $(6.1) million for the quarter.
• Operating expenses increased by 27% year-over-year, reflecting ongoing investments.
• The company increased its full-year operating expense guidance, indicating higher spending.

Risks

• The company's future performance is subject to risks and uncertainties, including the ability to maintain cash balances and successfully commercialize products.
• The company's actual results may differ materially from forward-looking statements due to various factors, including market conditions and competition.
• The company is still operating at a loss, and continued investment is required to achieve profitability.

Future Outlook

The company increased its full-year 2024 revenue guidance to $139.0 million to $140.0 million and operating expense guidance to $135.0 million to $136.0 million. Gross margin full-year 2024 guidance remained unchanged in the range of 68% to 70%.

Management Comments

• Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, stated that the company continued to make significant progress in the adoption of adjustability as a new standard in the premium market.
• Dr. Kurtz also highlighted the robust LDD sales and the positive reception of the recently launched LAL+.
• Management believes the ability to adjust the optical power of the lens after surgery is increasingly valued by both doctors and patients.

Industry Context

This announcement indicates a strong growth trajectory for RxSight in the premium intraocular lens (IOL) market, driven by the increasing adoption of adjustable lens technology. The company's focus on innovation and personalized vision solutions positions it well within the competitive landscape of ophthalmic medical devices.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 68% revenue growth and 92% increase in LAL sales suggest RxSight is outperforming many of its peers in the premium IOL market.
• Companies like Alcon and Johnson & Johnson Vision are major players in the IOL market, but RxSight's unique adjustable lens technology provides a competitive advantage.
• The 69.5% gross margin is strong and indicates efficient production and pricing strategies, which is a key metric for medical device companies.
• The increase in LDD installed base to 810 units shows a growing market presence and adoption of their technology, which is a key indicator of future revenue potential.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial performance positively.
• Employees may benefit from the company's growth and expansion.
• Customers (doctors and patients) will benefit from the continued innovation and availability of the adjustable lens technology.
• Suppliers may see increased demand for their products and services due to the company's growth.

Next Steps

• The company will host a conference call on August 5, 2024, to discuss its second quarter 2024 financial results.
• The company will continue to focus on expanding its presence and driving innovation within the global premium IOL market.
• The company will continue to invest in growing its LDD installed base and supporting increased LAL sales volume.

Key Dates

Keywords

RxSight, Light Adjustable Lens, LAL, Light Delivery Device, LDD, Ophthalmic Medical Device, Cataract Surgery, Revenue Growth, Financial Results, Gross Profit, Net Loss, Adjusted Net Earnings, Guidance